ADARx Director Reports Options on 267,792 Shares

One-quarter of the option shares first vest on July 20, 2027; remaining shares vest quarterly over three years, subject to continued service.

Rhea-AI Filing Summary

ADARx Pharmaceuticals, Inc. director Huang Ying reported a directly held stock option covering 267,792 common shares, with an exercise price of 8.69 per share and an expiration date of July 19, 2036. The option was granted July 20, 2026. One-quarter of the shares vest and become exercisable on July 20, 2027; the remainder vest in equal quarterly installments over the following three years, subject to continued service on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Huang Ying

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) F1	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 267,792 contracts (Direct)

Footnotes (1)

1. F1. Granted to the Reporting Person on July 20, 2026. 1/4 of the total number of shares vest and become exercisable on July 20, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Key Figures

Option shares underlying: 267,792 common shares Exercise price: 8.69 per share First vesting date: July 20, 2027 +1 more

4 metrics

Option shares underlying 267,792 common shares Directly held stock option

Exercise price 8.69 per share Stock option

First vesting date July 20, 2027 One-quarter of the option shares vest and become exercisable

Expiration date July 19, 2036 Stock option

Key Terms

Stock Option (right to buy), exercisable, equal quarterly installments

3 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

exercisable technical

"vest and become exercisable"

equal quarterly installments financial

"in equal quarterly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ADARx (ADRX) option shares did Huang Ying report?

Huang Ying reported a directly held stock option covering 267,792 common shares.

What is the exercise price of Huang Ying’s ADARx (ADRX) option?

The option’s exercise price is 8.69 per share.

When do Huang Ying’s ADARx (ADRX) option shares vest?

One-quarter of the shares vest and become exercisable on July 20, 2027. The remaining shares vest in equal quarterly installments over a three-year period, subject to continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/26/2026 - 08:34 PM Accepted by SEC EDGAR 09/24/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Huang Ying

(Last) (First) (Middle)

C/O ADARX PHARMACEUTICALS, INC.

5871 OBERLIN DRIVE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/24/2026

3. Issuer Name and Ticker or Trading Symbol
ADARx Pharmaceuticals, Inc. [ ADRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	07/19/2036	Common Stock	267,792	$8.69	D

Explanation of Responses:

1. Granted to the Reporting Person on July 20, 2026. 1/4 of the total number of shares vest and become exercisable on July 20, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jiang Bian , Attorney-in-Fact	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)